Table 2.

Activity of i.v. administered MPC-6827 in female Crl:Nu/Nu mouse xenograft models

Xenograft modelDose of MPC-6827 (mg/kg)Dosing regimen% Tumor growth inhibitionP
B16-F12.5q1w × 251 (d11)0.0017
5q1w × 267 (d11)<0.0001
OVCAR-35q3d × 488 (d32)0.0028
7.5q1w × 395 (d32)0.0001
HT-295q1w × 329 (d22)0.037
MIA PaCa5q1w × 349 (d18)0.02
MCF-75q1w × 353 (d22)0.003
10q1w × 371 (d22)0.0006
MX-12.5q1w × 370 (d27)0.02
5.0q1w × 396 (d27)0.002
MDA MB-4352.5q1w × 758 (d54)0.08
5.0q1w × 771 (d54)0.04
  • NOTE: MPC-6827 treatment significantly inhibits the growth of established tumor allografts and xenografts in athymic mice. The indicated tumors were established as s.c. allografts or xenografts in athymic nude mice. Treatment with i.v. MPC-6827 was initiated on the day the average tumor volume achieved 100 mm3 (N = 10). The subsequent maximal tumor growth inhibition values are listed with the day the measurement was made post-initial dose in parentheses.